“Michael’s contributions and unwavering determination to Dynavax have been important to the accomplishment of our company. We are really fortunate to have had his steering about the decades and now as a strategic advisor to assure a seamless changeover to his successor,” commented Ryan Spencer, Main Executive Officer of Dynavax. “Kelly is an accomplished financial chief with a deep knowing of corporate and business finance and will be an asset as we improve our business enterprise of creating vaccines to assistance protect against the spread of infectious diseases. On behalf of the board and the other associates of the executive staff, it is a satisfaction to welcome Kelly to Dynavax.”
“This is an exciting time to sign up for Dynavax as it continues to develop a leading vaccine company, addressing urgent international health and fitness needs,” commented Kelly MacDonald. “I share the extended-expression determination to Dynavax’ vision of collaboration, innovation and progress and look forward to leading the finance and accounting group in executing the company’s strategic and financial objectives.”
Ms. MacDonald joins Dynavax from Ironwood Prescription drugs exactly where she held roles of expanding accountability. In her last purpose at Ironwood Ms. MacDonald served as Chief Accounting Officer and Vice President, Finance where she led the Firm’s company accounting and finance procedures, company risk administration, treasury and funds allocation approach. While at Ironwood, she also held many other managerial roles, supplying finance and accounting support for the firm’s strategic arranging, R&D portfolio administration, world organization advancement, product launches and commercial execution. Prior to signing up for Ironwood, Kelly was a Supervisor in the Overall health Industries Assurance Apply at PricewaterhouseCoopers, mostly serving customers in daily life sciences and technological know-how sectors.
Ms. MacDonald is a Certified General public Accountant (CPA) and retains a Grasp of Enterprise Administration from the Isenberg College of Administration at the College of Massachusetts and a Bachelor of Science in Accounting from Fairfield College.
Dynavax is a commercial stage biopharmaceutical business producing and commercializing novel vaccines. The Firm’s 1st industrial solution, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is authorized in the U.S. for avoidance of an infection prompted by all known subtypes of hepatitis B virus in grown ups age 18 several years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant via investigation collaborations and partnerships. Present-day collaborations are concentrated on adjuvanted vaccines for COVID-19, pertussis and common influenza. For far more data, pay a visit to www.dynavax.com and follow the firm on LinkedIn.
Nicole Arndt, Senior Supervisor, Trader Relations
Derek Cole, President
Investor Relations Advisory Methods
Source Dynavax Systems